Great news from the 2013 AASLD Liver Meeting regarding a new, lower-dose formulation of Tenofovir for the treatment of hepatitis B
Published Thursday, 21 November 2013 00:00Written by Liz Highleyman
A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 64thAASLD Liver Meeting this month in Washington, DC. Continue reading "Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity"
— Christine M. Kukka, Project Manager, HBV Advocate
A new study suggests for the first time that the combination of the hepatitis B vaccine and HBIG (hepatitis B immune globulin) may be ineffective in preventing “occult” hepatitis B in babies born to mothers infected with the hepatitis B virus (HBV). An occult infection occurs when a person tests negative for the hepatitis B surface antigen (HBsAg)—considered an essential antigen building block for HBV—while testing positive for HBV DNA. When this occult infection occurs, researchers suspect the HBsAg has somehow mutated so conventional lab tests can’t identify it. Continue reading "Study Suggests Vaccine and HBIG Ineffective at Preventing “Occult” Hepatitis B in Babies Born to Infected Mothers"
Published on Monday, 11 November 2013
Written by Liz Highleyman
A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated as second-line therapy for chronic hepatitis B patients who had failed previous nucleoside/nucleotide treatment, according to a poster presentation at the 64th AASLD Liver Meeting last week in Washington, DC. Continue reading "Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure"
Harnessing the Power of RNAi Gene Silencing in a Quest of a Cure for Chronic Hepatitis B, and the HBV KnockDown blog written by Dirk Haussecker, who believes it’s about time everyone got serious about a functional cure for hepatitis B.
As I was reading the latest PK-PD study by Gilead on its lead experimental chronic HepB drug candidate GS-9620 (Fosdick et al. 2013), it finally dawned on me that much-touted GS-9620 has been designed to be nothing more than a better tolerated, more convenient version of an already existing treatment option, recombinant interferon. GS-9620 is therefore an example of the typical incrementalist Big Pharma value creation strategy. By contrast, if successful, an HBsAg knockdown approach such as with Arrowhead’s ARC520 would bring to healthcare providers and patients an entirely new, desperately needed treatment option as the field has become stuck with interferons and RT inhibitors for years. Continue reading "Gilead Lead Chronic HepB Candidate GS-9620 Conceived as a More Patient-Friendly Interferon"
HBF is pleased to connect our blog readers to Christine Kukka’s monthly HBV Journal Review that she writes for the HBV Advocate. The journal presents the
latest in hepatitis B research, treatment, and prevention from recent academic and medical journals. This month, the following topics are explored:
- Patients Who Clear Hepatitis B During Antiviral Treatment Do Well Long-Term
- However, the Prognosis is Poor for Most Who Stop Antiviral Treatment
- How Effective Are Antivirals in Reducing Cirrhosis and Preventing Liver Cancer?
- New Antiviral Besifovir Hampered by Carnitine Deficiency in Early Clinical Trial
- Liver Cancer Remains Major Health Threat, with Few Treatment Options
- Scientists Develop a Better Mouse for Hepatitis B and C Research
- HBV-Infected People Have a Higher Risk of Rheumatoid Arthritis
- Ear Wax May Transmit Hepatitis B
- Children with Frequent Ear Infections Do Not Respond as Well to Vaccines
- Clean-Shave Haircuts Leave Traces of Virus on the Scalp Continue reading "HBV Journal Review – November 2013"